FDA adds Class I tag to Dräger’s recall of 36K ventilator filters
FDA adds Class I tag to Dräger’s recall of 36K ventilator filters
apark
Wed, 06/22/2022 - 11:53
GE Healthcare debuts wireless, wearable hospital patient monitor
GE Healthcare debuts wireless, wearable hospital patient monitor
chale
Wed, 06/22/2022 - 10:24
Medtronic reinforces spine surgery portfolio with FDA nod for ligament-augmenting implant
Medtronic reinforces spine surgery portfolio with FDA nod for ligament-augmenting implant
apark
Wed, 06/22/2022 - 10:23
Appetite for allergies: Alladapt banks $119M to push immunotherapy through trials
Appetite for allergies: Alladapt banks $119M to push immunotherapy through trials
jwaldron
Wed, 06/22/2022 - 10:03
Beacon of Hope: Novartis commits $17.7M to set up clinical trial centers in historically Black medical schools
Beacon of Hope: Novartis commits $17.7M to set up clinical trial centers in historically Black medical schools
jwaldron
Wed, 06/22/2022 - 08:57
Frying pan, meet fire: Athira flunks Alzheimer's trial to pile on the pain ahead of phase 3 data drop
Frying pan, meet fire: Athira flunks Alzheimer's trial to pile on the pain ahead of phase 3 data drop
ntaylor
Wed, 06/22/2022 - 06:57
Novartis plots Precision attack on sickle cell, paying $75M and putting up $1.4B in biobucks to form in vivo gene editing pact
Novartis plots Precision attack on sickle cell, paying $75M and putting up $1.4B in biobucks to form in vivo gene editing pact
ntaylor
Wed, 06/22/2022 - 03:41
CRISPR Tx's Innovation Day dragged down by multiple myeloma replacement, lackluster results in kidney cancer
CRISPR Tx's Innovation Day dragged down by multiple myeloma replacement, lackluster results in kidney cancer
gmasson
Tue, 06/21/2022 - 23:37
Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push
Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push
aarmstrong
Tue, 06/21/2022 - 20:57
Patient empowerment goes from 'trend to permanent movement' as cancer trial interest grows
Patient empowerment goes from 'trend to permanent movement' as cancer trial interest grows
aarmstrong
Tue, 06/21/2022 - 19:27
9 Meters’ celiac drug doesn’t measure up in phase 3
9 Meters’ celiac drug doesn’t measure up in phase 3
gmasson
Tue, 06/21/2022 - 13:20
Human Longevity seeks new life with proposed SPAC deal
Human Longevity seeks new life with proposed SPAC deal
chale
Tue, 06/21/2022 - 12:22
PathAI co-founder Khosla carves a new path as CTO of Iterative Scopes
PathAI co-founder Khosla carves a new path as CTO of Iterative Scopes
apark
Tue, 06/21/2022 - 12:11
Enzyme inhibitor could counter bad 'seeds' that let leukemia bounce back
Enzyme inhibitor could counter bad 'seeds' that let leukemia bounce back
jwaldron
Tue, 06/21/2022 - 10:52
Bioventus reworks $450M CartiHeal acquisition after scrapping original debt financing plan
Bioventus reworks $450M CartiHeal acquisition after scrapping original debt financing plan
apark
Tue, 06/21/2022 - 10:14
Proofpilot, Greater Gift team on research diversity initiative
Proofpilot, Greater Gift team on research diversity initiative
aarmstrong
Tue, 06/21/2022 - 09:42
Merck's next-gen pneumococcal vaccine slated for July phase 3 after two-part win
Merck's next-gen pneumococcal vaccine slated for July phase 3 after two-part win
jwaldron
Tue, 06/21/2022 - 08:02
Lyme-light: Pfizer triggers surge in Valneva’s stock with €91M investment to support phase 3 vaccine trial
Lyme-light: Pfizer triggers surge in Valneva’s stock with €91M investment to support phase 3 vaccine trial
ntaylor
Tue, 06/21/2022 - 07:40
Hot on Alnylam’s heels, AstraZeneca racks up phase 3 win for Ionis-partnered rare disease drug
Hot on Alnylam’s heels, AstraZeneca racks up phase 3 win for Ionis-partnered rare disease drug
ntaylor
Tue, 06/21/2022 - 05:43
Decentralized trials an agile solution for cancer R&D, says Science 37
Decentralized trials an agile solution for cancer R&D, says Science 37
aarmstrong
Fri, 06/17/2022 - 15:12